Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merel L Hartgers

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Cardiology Reports|October 21, 2015
New Approaches in Detection and Treatment of Familial HypercholesterolemiaMerel L Hartgers, Kausik K Ray, G Kees Hovingh
European Journal of Preventive Cardiology|June 24, 2017
Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitorsIvan Pećin, Merel L Hartgers, G Kees Hovingh, et al.
Atherosclerosis|December 20, 2017
PCSK9 inhibitors in clinical practice: Delivering on the promise?Robert M Stoekenbroek, Merel L Hartgers, Roger Rutte, et al.
Journal of Clinical Lipidology|February 24, 2019
The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: Results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) studyIlse K Luirink, Marjet J A M Braamskamp, Albert Wiegman, et al.
Journal of Clinical Lipidology|December 7, 2016
Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported diseaseBarbara Sjouke, Joep C Defesche, Merel L Hartgers, et al.
Circulation. Genomic and Precision Medicine|December 19, 2018
A Deep Intronic Variant in LDLR in Familial HypercholesterolemiaLaurens F Reeskamp, Merel L Hartgers, Jorge Peter, et al.
Atherosclerosis|July 31, 2024
LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemiaShirin Ibrahim, Merel L Hartgers, Laurens F Reeskamp, et al.
Journal of Clinical Lipidology|February 4, 2018
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemiaMerel L Hartgers, Joep C Defesche, Gisle Langslet, et al.
Journal of the American Heart Association|October 8, 2024
Ursodeoxycholic Acid for Trans Intestinal Cholesterol Excretion Stimulation: A Randomized Placebo Controlled Crossover StudyReindert F Oostveen, Yannick Kaiser, Merel L Hartgers, et al.
Lancet (London, England)|February 1, 2022
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort studyTycho R Tromp, Merel L Hartgers, G Kees Hovingh, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Cardiology Reports|October 21, 2015
New Approaches in Detection and Treatment of Familial HypercholesterolemiaMerel L Hartgers, Kausik K Ray, G Kees Hovingh
European Journal of Preventive Cardiology|June 24, 2017
Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitorsIvan Pećin, Merel L Hartgers, G Kees Hovingh, et al.
Atherosclerosis|December 20, 2017
PCSK9 inhibitors in clinical practice: Delivering on the promise?Robert M Stoekenbroek, Merel L Hartgers, Roger Rutte, et al.
Journal of Clinical Lipidology|February 24, 2019
The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: Results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) studyIlse K Luirink, Marjet J A M Braamskamp, Albert Wiegman, et al.
Journal of Clinical Lipidology|December 7, 2016
Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported diseaseBarbara Sjouke, Joep C Defesche, Merel L Hartgers, et al.
Circulation. Genomic and Precision Medicine|December 19, 2018
A Deep Intronic Variant in LDLR in Familial HypercholesterolemiaLaurens F Reeskamp, Merel L Hartgers, Jorge Peter, et al.
Atherosclerosis|July 31, 2024
LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemiaShirin Ibrahim, Merel L Hartgers, Laurens F Reeskamp, et al.
Journal of Clinical Lipidology|February 4, 2018
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemiaMerel L Hartgers, Joep C Defesche, Gisle Langslet, et al.
Journal of the American Heart Association|October 8, 2024
Ursodeoxycholic Acid for Trans Intestinal Cholesterol Excretion Stimulation: A Randomized Placebo Controlled Crossover StudyReindert F Oostveen, Yannick Kaiser, Merel L Hartgers, et al.
Lancet (London, England)|February 1, 2022
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort studyTycho R Tromp, Merel L Hartgers, G Kees Hovingh, et al.
Pageof 2